Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
13 "Su-Jin Koh"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Exploring Oncologists’ Perspectives on the Early Integration of Specialty Palliative Care in Korea: Challenges, Needs, and Clinical Implications
Shin Hye Yoo, Yu Jung Kim, Ye Sul Jeung, Jung Sun Kim, Kwonoh Park, Eun Mi Nam, Si Won Lee, Jun Ho Ji, Jwa Hoon Kim, Joon Young Hur, Song Ee Park, Jung Lim Lee, Su-Jin Koh
Received February 11, 2025  Accepted April 9, 2025  Published online April 10, 2025  
DOI: https://doi.org/10.4143/crt.2025.158    [Accepted]
AbstractAbstract PDF
Purpose
This study aimed to explore the practices, perceptions, and barriers related to specialty palliative care (SPC) referrals among oncologists in Korea, highlighting the clinical implications of early integration.
Materials and Methods
A cross-sectional online survey targeting board-certified hemato-oncology specialists was conducted between August 1–25, 2024. The survey assessed referral practices, attitudes toward early SPC integration, referral criteria, barriers, and institutional characteristics.
Results
A total of 227 oncologists participated (response rate: 36.7%). Among them, 68.7% reported frequent SPC referrals, with higher referral rates observed among younger physicians, those in tertiary hospitals, and institutions with in-house SPC teams (p<0.001). Although 74.9% supported early SPC integration, referrals were often inconsistently timed, frequently occurring after disease progression or at the discontinuation of chemotherapy. For time-based referrals, the most commonly endorsed triggers were disease progression despite palliative second-line treatment and a prognosis of expected mortality within 6–12 months. Need-based referral triggers such as patient or family requests (96.5%), psychological distress (89.9%), or uncontrolled symptoms (83.3%), were also widely endorsed. The major barriers to early SPC integration included patient and family resistance (70.0%) and limited availability of SPC teams (34.4%).
Conclusion
This study emphasizes the importance of systematic efforts to promote timely SPC integration in Korea, including education to raise patient awareness, improved referral systems, and enhanced infrastructure. The positive attitudes toward early SPC among oncologists reflect a growing recognition of its value, highlighting the need for strategies that align with international standards.
  • 191 View
  • 16 Download
Close layer
A Prospective, Single-Cohort, Open, Multi-Center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients
Youn Seon Choi, Su-Jin Koh, Woo Kyun Bae, Se Hyung Kim, Seong Hoon Shin, So Yeon Oh, Sang Byung Bae, Yaewon Yang, Eun-Kee Song, Yoon Young Cho, Pyung Bok Lee, Ho-Suk Oh, MinYoung Lee, Jin Seok Ahn
Received June 13, 2024  Accepted December 24, 2024  Published online December 26, 2024  
DOI: https://doi.org/10.4143/crt.2024.557    [Accepted]
AbstractAbstract PDF
Purpose
Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, controlled study. We investigated the effectiveness and safety of SFT administered to alleviate BTcP in a real-world setting.
Materials and Methods
In this prospective, open, single-cohort study, conducted in 13 referral hospitals in South Korea, opioid-tolerant cancer patients receiving around-the-clock opioids for persistent cancer pain were enrolled if the individual had BTcP ≥ 1 episode/day during the preceding week. The primary outcome was the SFT titration success rate.
Results
Among 113 patients evaluated for effectiveness, 103 patients (91.2%) had a successful titration of SFT, with an effective dose range between 100 µg and 400 µg. The most frequent dose was 100 µg, administered to 65.0%, 72.1%, and 81.8% of the patients at Week 1, 4, and 12, respectively. The proportion of patients achieving the personalized pain goal assessed in the first week was 75.2%. The mean change in pain intensity measured with a numeric rating scale at 30 and 60 minutes after taking SFT was -2.57 and -3.62, respectively (p<0.0001 for both). The incidence rate of adverse events related to SFT among 133 patients included for safety evaluation was 9.0% (12/133), which included vomiting (3.0%), nausea (2.3%), and headache (1.5%).
Conclusion
In a real-world setting, SFT provides rapid and effective analgesia in BTcP, even at the lowest dose (100 μg), and the safety profile was acceptable.
  • 587 View
  • 66 Download
Close layer
Psychometric Validation of Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients
Hong Jun Kim, Eun Hee Jung, Jung Hye Kwon, Yu Jung Kim, Su-Jin Koh, Myung Ah Lee, Jung Hun Kang, Sun Young Rha, Eun Mi Nam, Sun Kyung Baek, Ha Yeon Lee, Hun Ho Song, Young-Woong Won, Hanbyul Lee
Received July 26, 2024  Accepted December 4, 2024  Published online December 5, 2024  
DOI: https://doi.org/10.4143/crt.2024.706    [Epub ahead of print]
AbstractAbstract PDFSupplementary Material
Purpose
Identifying the palliative care needs of patients with advanced cancer is important for maintaining quality of life and timely transition to palliative care. We aimed to validate the Korean Sheffield Profile for Assessment and Referral for Care (K-SPARC) in such patients and establish its psychometric properties, including reliability, validity, and responsiveness to change.
Materials and Methods
We used the forward-back translated version of SPARC, which was verified through a pilot study, to assess the palliative care needs of patients with advanced cancer. Reliability was evaluated by internal consistency using Cronbach's alpha coefficients and test-retest reliability. Criterion validity was analyzed against other questionnaires, including the Korean versions of the Functional Assessment of Cancer Therapy-General (FACT-G Korean) and Korean versions of the Edmonton Symptom Assessment System (K-ESAS). Factor analysis was used to assess construct validity.
Results
Two hundred fifty-nine patients were included from 2019 to 2022. Forty-nine percent of all patients were women, and the median age was 63 years. Cronbach’s alpha coefficient (range, 0.642 to 0.903) and test-retest reliability (range, 0.574 to 0.749) indicated acceptable reliability. The correlation coefficients between K-SPARC and FACT-G Korean suggested significant criterion validity. The correlation coefficients for the physical, social, emotional, and functional domains were 0.701, 0.249, 0.718, and 0.511, respectively (p < 0.001, all). Factor analysis demonstrated satisfactory construct validity of the tool.
Conclusion
This study demonstrated the utility of K-SPARC as an evaluation tool for providing palliative care to patients with advanced cancer through psychometric validation; the tool had good internal consistency, reliability, and acceptable validity.
  • 591 View
  • 45 Download
Close layer
General
Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer
Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock
Cancer Res Treat. 2024;56(4):1040-1049.   Published online April 9, 2024
DOI: https://doi.org/10.4143/crt.2024.003
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A “Smart Cancer Care” platform that integrates patient-reported outcomes (PROs) with management has been established in Korea. This study focused on improving health behaviors and connecting patients to welfare services by introducing and assessing the feasibility of “Smart Cancer Care 2.0,” an enhanced version designed for monitoring complications post-cancer treatment.
Materials and Methods
Smart Cancer Care 2.0 was developed by conducting a literature review and consulting with expert panels to identify symptoms or variables requiring monitoring and management guidelines based on the treatment type. Qualitative and quantitative surveys were conducted to assess the feasibility of the app and web system based on the experiences of patients with cancer and healthcare workers.
Results
A total of 81 symptoms or variables (chemotherapy-, surgery-, radiotherapy-, rehabilitation-, and health management-related) were selected for management in Smart Cancer Care 2.0. PROs for these symptoms were basically categorized into three severity grades: preventive management, self-treatment, and consultation with a healthcare worker or visit to a healthcare institution. The overall mean scores in the feasibility evaluation by patients and healthcare workers were 3.83 and 3.90 points, respectively, indicating high usefulness.
Conclusion
Smart Cancer Care 2.0 leverages the existing information and communication technologies–based platform, Smart Cancer Care, and further includes health behaviors and welfare services. Smart Cancer Care 2.0 may play a crucial role in establishing a comprehensive post-discharge management system for patients with cancer as it provides suitable interventions based on patients’ responses and allows the regularly collected PROs to be easily viewed for streamlined care.
  • 2,088 View
  • 122 Download
Close layer
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study
Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Sang-We Kim, Dae Ho Lee, Jae Cheol Lee, Chang-Min Choi, Shinkyo Yoon, Su-Jin Koh, Young Joo Min, Yongchel Ahn, Hwa Jung Kim, Jin Ho Baek, Sook Ryun Park, Jee Hyun Kim
Cancer Res Treat. 2024;56(2):404-413.   Published online November 7, 2023
DOI: https://doi.org/10.4143/crt.2023.784
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex.
Materials and Methods
This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea.
Results
A total of 1,170 patients with colorectal, gastric, or non–small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade ≥ 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits.
Conclusion
Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions.

Citations

Citations to this article as recorded by  
  • Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
    Elizabeth J. Cathcart‐Rake, Alexandre Chan, Alvaro Menendez, Denise Markstrom, Carla Schnitzlein, Yee Won Chong, Don S. Dizon
    CA: A Cancer Journal for Clinicians.2025; 75(1): 68.     CrossRef
  • Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats
    Chiara Di Marino, Álvaro Llorente-Berzal, Alba M. Diego, Ariadni Bella, Laura Boullon, Esther Berrocoso, Michelle Roche, David P. Finn
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • [Translated article] Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer
    María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
    Farmacia Hospitalaria.2025;[Epub]     CrossRef
  • The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma
    Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, Mujtaba Khalil, Miho Akabane, François Cauchy, Feng Shen, Shishir Maithel, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, Luca Aldrighetti, George Poultsides, Andrea Ru
    Annals of Surgical Oncology.2025;[Epub]     CrossRef
  • Toxicidad del esquema FOLFOX-6, asociado o no a bolo de 5-fluorouracilo, en cáncer colorrectal metastásico
    María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
    Farmacia Hospitalaria.2024;[Epub]     CrossRef
  • 3,665 View
  • 167 Download
  • 3 Web of Science
  • 5 Crossref
Close layer
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim
Cancer Res Treat. 2023;55(4):1096-1103.   Published online April 7, 2023
DOI: https://doi.org/10.4143/crt.2022.1565
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by  
  • Ethanol intoxication in paediatric patients receiving intravenous etoposide as conditioning regimen for allogenic hematopoietic stem cell transplant
    Pauline Claraz, Marie de Tersant, Valentine Feyants, Julie Roupret-Serzec, Thomas Storme, Jean-Hugues Dalle
    Journal of Oncology Pharmacy Practice.2025;[Epub]     CrossRef
  • Evaluation of self-assembling properties of paclitaxel-biotin conjugates
    Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
    Nano-Structures & Nano-Objects.2024; 40: 101375.     CrossRef
  • 3,777 View
  • 220 Download
  • 2 Crossref
Close layer
Breast cancer
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, Soojung Hong, Sun Kyung Baek, Soon Il Lee, Moon Young Choi, In Sook Woo
Cancer Res Treat. 2023;55(1):123-135.   Published online March 24, 2022
DOI: https://doi.org/10.4143/crt.2021.1561
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.
Materials and Methods
We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.
Results
The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).
Conclusion
Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.

Citations

Citations to this article as recorded by  
  • HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients
    Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang
    Scientific Reports.2025;[Epub]     CrossRef
  • Male breast cancer - a single center experience
    Igor Djurisic, Milan Zegarac, Milan Kocic, Vladimir Jokic, Nikola Vucic, Ognjen Petrovic, Nada Santrac, Jovana Koncar, Andjela Ivezic, Srdjan Nikolic
    Srpski arhiv za celokupno lekarstvo.2025; 153(1-2): 53.     CrossRef
  • Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer
    Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang
    American Journal of Men's Health.2024;[Epub]     CrossRef
  • 6,134 View
  • 181 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
General
Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era
Kyumin Kim, Harin Kim, Joohee Lee, Inn-Kyu Cho, Myung Hee Ahn, Ki Young Son, Jeong Eun Kim, Hee Jeong Kim, Sang Min Yoon, So Hee Kim, Moon Jung Kwon, Hwa Jung Kim, Su-Jin Koh, Seyoung Seo, Seockhoon Chung
Cancer Res Treat. 2022;54(3):671-679.   Published online September 17, 2021
DOI: https://doi.org/10.4143/crt.2021.585
AbstractAbstract PDFPubReaderePub
Purpose
Literature is scarce regarding cancer care utilization during the massive outbreak of coronavirus disease 2019 (COVID-19) in the Republic of Korea. We investigated functional impairments in mental health and their relationships with depression, anxiety regarding the viral epidemic, and disruptions in healthcare service utilization among cancer patients in the COVID-19 pandemic era.
Materials and Methods
We used an online survey with questions related to the disturbances faced by patients with cancer in utilizing healthcare services in the pandemic era. Current mental health status was assessed using the Work and Social Adjustment Scale (WSAS), Stress and Anxiety to Viral Epidemics-6 (SAVE-6) scale, Patient Health Questionnaire-9 (PHQ-9), Insomnia Severity Index (ISI), Brief Resilience Scale (BRS), Cancer-Related Dysfunctional Beliefs about Sleep Scale (C-DBS), and Fear of COVID-19 over Cancer (FCC).
Results
Among the 221 responders, 95 (43.0%) reported disruptions in healthcare service utilization during the COVID-19 pandemic. Logistic regression analysis revealed that functional impairment in the mental health of these patients was expected due to disruptions in healthcare service utilization, high levels of depression, anxiety regarding the viral epidemic, fear of COVID over cancer, and low resilience. Mediation analysis showed that patient resilience and cancer-related dysfunctional beliefs about sleep partially mediated the effects of viral anxiety on functional impairment.
Conclusion
In this pandemic era, patients with cancer experience depression, anxiety regarding the viral epidemic, and disruptions in healthcare service utilization, which may influence their functional impairments in mental health.

Citations

Citations to this article as recorded by  
  • The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations
    Amanda L King, Kayla N Roche, Elizabeth Vera, Valentina Pillai, Lily Polskin, Alvina A Acquaye-Mallory, Lisa Boris, Eric Burton, Anna Choi, Ewa Grajkowska, Heather E Leeper, Marissa Panzer, Marta Penas-Prado, Jennifer Reyes, Solmaz Sahebjam, Brett J Theel
    Neuro-Oncology Practice.2025; 12(1): 76.     CrossRef
  • Prevalence of depressive symptoms and correlates among individuals who self-reported SARS-CoV-2 infection after optimizing the COVID-19 response in China
    Liangjia Wei, Jiao Qin, Zhifeng Lin, Xinju Huang, Jinfeng He, Dee Yu, Fei Zhang, Sisi Li, Ping Cen, Mu Li, Tong Luo, Rongjing Zhang, Shanmei Zhong, Cai Qin, Zeyu Li, Yuan Yang, Huiqi Pan, Mengdi Zhao, Xiaoqiong Wu, Junjun Jiang, Hao Liang, Li Ye, Bingyu L
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Evaluation of mental health of students in healthcare education programs at Qatar University
    Ola Hayk, Abdulla Mansoor, Shahd Al-Najdi, Alaa Daud, Rula Shami, Najah Al-Hashimi, Kamran Ali
    MedEdPublish.2024; 14: 37.     CrossRef
  • Inpatient Hospice Care in Korea during the COVID-19 Pandemic: A Preliminary Study
    Youn Seon Choi, Sun Wook Hwang, In Cheol Hwang
    Journal of Hospice and Palliative Care.2024; 27(2): 82.     CrossRef
  • Risk factors for heightened COVID‐19‐Related anxiety among breast cancer patients
    Yash B. Shah, Stephanie Kjelstrom, Diana Martinez, Adam Leitenberger, Donna‐Marie Manasseh, Melissa Bollmann‐Jenkins, Ann Partridge, Virginia Kaklamani, Rowen Chlebowski, Sharon Larson, Marisa Weiss
    Cancer Medicine.2023; 12(3): 3577.     CrossRef
  • Discrepancy between desired time in bed and desired total sleep time in patients with cancer: The DBST index and its relationship with insomnia severity and sleep onset latency
    Eulah Cho, Jaeeun Song, Joohee Lee, Inn-Kyu Cho, Dongin Lee, Hayun Choi, Harin Kim, Seockhoon Chung
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Health-related quality of life and depressive symptoms of patients with chronic diseases and the general population before and during the COVID-19 pandemic in Korea
    Yeeun Park, Kyong Park
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • A study of COVID anxiety, spiritual well-being and resilience levels in patients with cancer undergoing chemotherapy during the COVID-19 pandemic: a cross-sectional study in the south of Iran
    Zahra Khiyali, Zeinab Naderi, Mohammadkazem Vakil, Hajar Ghasemi, Azizallah Dehghan, Mostafa Bijani
    BMC Psychology.2023;[Epub]     CrossRef
  • Does Viral Anxiety Influence the Insomnia Severity Among Patients With Insomnia Disorder During COVID-19 Pandemic?
    Jana Sleiman, Eulah Cho, Dongin Lee, Inn-Kyu Cho, Seockhoon Chung, Omer Faruk Uygur
    Sleep Medicine Research.2023; 14(1): 25.     CrossRef
  • Associations of psychological status and ultrasonic characteristics of thyroid nodules in adults during the COVID-19 pandemic
    Zhengwu Lei, Zhongxiang He, Ying Mei, Xiaoya Qi, Pingping Yu, Guoqiong Xu, Hongfeng Cheng, Ruixue Bai, Jing Deng
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • The Impact of COVID-19 on Psychiatric Health in the Korean Population
    Sheng-Min Wang, Sung-Hwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bahk
    Clinical Psychopharmacology and Neuroscience.2023; 21(3): 410.     CrossRef
  • Adherence to Physical Distancing and Health Beliefs About COVID-19 Among Patients With Cancer
    Sajida Fawaz Hammoudi, Oli Ahmed, Hoyoung An, Youjin Hong, Myung Hee Ahn, Seockhoon Chung
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic
    Hyuk Joo Lee, Cheolkyung Sin, Hyeyeong Kim, Hyeon-Su Im, Jae-Cheol Jo, Yoo Jin Lee, Youjin Kim, Junseok Ahn, Soyoung Yoo, Su-Jin Koh, Seockhoon Chung
    Psychiatry Investigation.2023; 20(12): 1204.     CrossRef
  • The role of social support and resilience in the mental health impact of the COVID-19 pandemic among healthcare workers in Spain
    Esther Ortiz-Calvo, Gonzalo Martínez-Alés, Roberto Mediavilla, Elisabeth González-Gómez, Eduardo Fernández-Jiménez, María-Fe Bravo-Ortiz, Berta Moreno-Küstner
    Journal of Psychiatric Research.2022; 148: 181.     CrossRef
  • The Validation Study of the Stress and Anxiety to Viral Epidemics−6 Scale Among Patients With Cancer in the COVID-19 Pandemic
    Hyeyeong Kim, Harin Kim, Hyuk Joo Lee, Eulah Cho, Su-Jin Koh, Oli Ahmed, Seockhoon Chung
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic
    Veronica Velasco-Durantez, Paula Jimenez-Fonseca, Carla M. Martín Abreu, Ismael Ghanem, Manuel González Moya, Elena Asensio, María J. Corral, Adan Rodriguez-Gonzalez, Mireia Gil-Raga, Alberto Carmona-Bayonas, Caterina Calderon
    Cancer Investigation.2022; 40(6): 475.     CrossRef
  • Mental Health in Postoperative Thyroid Patients During the COVID-19 Pandemic
    Shijie Yang, Xiequn Xu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Effect of Cancer-Related Dysfunctional Beliefs About Sleep on Fear of Cancer Progression in the Coronavirus Pandemic
    Harin Kim, Inn-Kyu Cho, Dongin Lee, Kyumin Kim, Joohee Lee, Eulah Cho, C. Hyung Keun Park, Seockhoon Chung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Insomnia Mediate the Influence of Reassurance-Seeking Behavior and Viral Anxiety on Preoccupation With COVID-19 Among the General Population
    Eulah Cho, Dongin Lee, Inn-Kyu Cho, Joohee Lee, Junseok Ahn, Young Rong Bang
    Sleep Medicine Research.2022; 13(2): 68.     CrossRef
  • Reliability and Validity of Dysfunctional Beliefs About Sleep-2 (DBS-2), an Ultra-brief Rating Scale for Assessing Dysfunctional Thoughts About Sleep
    Kyumin Kim, Seockhoon Chung, Eulah Cho, Jung Mun Choi, Dongin Lee, Inn-Kyu Cho
    Sleep Medicine Research.2022; 13(3): 165.     CrossRef
  • 10,154 View
  • 278 Download
  • 18 Web of Science
  • 20 Crossref
Close layer
Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, JinShil Kim, Su-Jin Koh
Cancer Res Treat. 2019;51(4):1632-1638.   Published online April 18, 2019
DOI: https://doi.org/10.4143/crt.2019.009
AbstractAbstract PDFPubReaderePub
Purpose
Physician Orders for Life-Sustaining Treatment (POLST) form is a legal document for terminally ill patients to make medical decisions with physicians near the end-of-life. A multicenter prospective study was conducted to evaluate the feasibility of POLST administration in actual oncological practice.
Materials and Methods
Patients with terminal cancer, age ≥ 20 years, and capable of communicating were eligible. The primary endpoint was the completion rate of POLST. Data about physicians’ or patients’ barriers were also collected.
Results
From June to December 2017, 336 patients from seven hospitals were eligible. Median patient age was 66 years (range, 20 to 94 years); 52.7% were male; and 60.4% had poor performance status. Primary cancer sites were hepato-pancreato-biliary (26.2%), lung (23.2%), and gastrointestinal (19.9%). Expected survival duration was 10.6±7.3 weeks, with 41.2% receiving hospice care, 37.9% showing progression after cancer treatment, and the remaining patients were under active treatment (15.8%) or initially diagnosed with terminal cancer (5.1%). POLST forms were introduced to 60.1% of patients, and 31.3% signed the form. Physicians’ barriers were reluctance of family (49.7%), lack of rapport (44.8%), patients’ denial of prognosis (34.3%), lack of time (22.7%), guilty feelings (21.5%), and uncertainty about either prognosis (21.0%) or the right time to discuss POLST (16.6%). The patients’ barriers were the lack of knowledge/understanding of POLST (65.1%), emotional discomfort (63.5%), difficulty in decision-making (66.7%), or denial of prognosis (14.3%).
Conclusion
One-third of patients completed POLST forms, and various barriers were identified. To overcome such barriers, social engagement, education, and systematic support might be necessary.

Citations

Citations to this article as recorded by  
  • Characteristics of Life-Sustaining Treatment Decisions: National Data Analysis in South Korea
    Jiyeon Choi, Heejung Jeon, Ilhak Lee
    Asian Bioethics Review.2024; 16(1): 33.     CrossRef
  • An Integrative Review of the State of POLST Science: What Do We Know and Where Do We Go?
    Elizabeth E. Umberfield, Matthew C. Fields, Rachel Lenko, Teryn P. Morgan, Elissa Schuler Adair, Erik K. Fromme, Hillary D. Lum, Alvin H. Moss, Neil S. Wenger, Rebecca L. Sudore, Susan E. Hickman
    Journal of the American Medical Directors Association.2024; 25(4): 557.     CrossRef
  • Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study
    Hyeon-Su Im, Insook Lee, Shinmi Kim, Jong Soo Lee, Ju-Hee Kim, Jae Young Moon, Byung Kyu Park, Kyung Hee Lee, Myung Ah Lee, Sanghoon Han, Yoonki Hong, Hyeyeoung Kim, Jaekyung Cheon, Su-Jin Koh
    BMC Medical Ethics.2023;[Epub]     CrossRef
  • Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement
    Dae Seog Heo, Shin Hye Yoo, Bhumsuk Keam, Sang Ho Yoo, Younsuck Koh
    The Korean Journal of Hospice and Palliative Care.2022; 25(1): 1.     CrossRef
  • Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
    Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh
    Supportive Care in Cancer.2022; 30(9): 7431.     CrossRef
  • The Medical Orders for Scope of Treatment (MOST) form completion: a retrospective study
    Anastasia A. Mallidou, Coby Tschanz, Elisabeth Antifeau, Kyoung Young Lee, Jenipher Kayuni Mtambo, Holly Heckl
    BMC Health Services Research.2022;[Epub]     CrossRef
  • Recommended summary plan for emergency care and treatment: ReSPECT a mixed-methods study
    Gavin D Perkins, Claire A Hawkes, Karin Eli, James Griffin, Claire Jacques, Caroline J Huxley, Keith Couper, Cynthia Ochieng, Jonathan Fuld, Zoe Fritz, Rob George, Doug Gould, Richard Lilford, Martin Underwood, Catherine Baldock, Chris Bassford, Peter-Mar
    Health and Social Care Delivery Research.2022; 10(40): 1.     CrossRef
  • Emergency Healthcare Providers’ Knowledge about and Attitudes toward Advance Directives: A Cross-Sectional Study between Nurses and Emergency Medical Technicians at an Emergency Department
    Sun Woo Hong, Shinmi Kim, Yu Jin Yun, Hyun Sook Jung, JaeLan Shim, JinShil Kim
    International Journal of Environmental Research and Public Health.2021; 18(3): 1158.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • We Want More Than Life-Sustaining Treatment during End-of-Life Care: Focus-Group Interviews
    Mirinae Kim, Minju Kim
    International Journal of Environmental Research and Public Health.2021; 18(9): 4415.     CrossRef
  • Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
    Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
    BMC Palliative Care.2021;[Epub]     CrossRef
  • Asian patients’ perspectives on advance care planning: A mixed-method systematic review and conceptual framework
    Diah Martina, Olaf P Geerse, Cheng-Pei Lin, Martina S Kristanti, Wichor M Bramer, Masanori Mori, Ida J Korfage, Agnes van der Heide, Judith AC Rietjens, Carin CD van der Rijt
    Palliative Medicine.2021; 35(10): 1776.     CrossRef
  • Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life
    Young-Woong Won, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Sun Kyung Baek, Yu Jung Kim, Do Yeun Kim, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 908.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Preference and Performance Fidelity of Modified Korean Physician Order for Life-Sustaining Treatment (MK-POLST) Items in Hospice Patients with Cancer
    Ji Hee Han, Hye Sook Chun, Tae Hee Kim, Rock Bum Kim, Jung Hoon Kim, Jung Hun Kang
    The Korean Journal of Hospice and Palliative Care.2019; 22(4): 198.     CrossRef
  • 8,633 View
  • 166 Download
  • 12 Web of Science
  • 15 Crossref
Close layer
Validity and Reliability of Korean Version of Simplified Nutritional Appetite Questionnaire in Patients with Advanced Cancer: A Multicenter, Longitudinal Study
So Yeon Oh, Su-Jin Koh, Ji Yeon Baek, Kyung A Kwon, Hei-Cheul Jeung, Kyung Hee Lee, Young-Woong Won, Hyun Jung Lee
Cancer Res Treat. 2019;51(4):1612-1619.   Published online April 12, 2019
DOI: https://doi.org/10.4143/crt.2018.505
AbstractAbstract PDFPubReaderePub
Purpose
Malnutrition and a loss of muscle mass are frequent in cancer patients and have a negative effect on clinical outcome. Nutrition risk screening aims to increase awareness and allow early recognition and treatment of cancer cachexia. Therefore, screenings should be brief, inexpensive, highly sensitive, and have good specificity. Simplified Nutritional Appetite Questionnaire (SNAQ) is a simple screening tool including four questions, and validated to predict weight loss within 6 months in community-dwelling adults and nursing home residents. Our study aimed to translate the SNAQ into Korean, and to assess the validity and reliability of the translated screening tool in advanced cancer patients.
Materials and Methods
The SNAQ was translated into Korean according to linguistic validation. The internal consistency of the SNAQ was evaluated by Cronbach’s alpha coefficient. Test-retest reliability was evaluated using the intraclass correlation coefficient. Concurrent validity was evaluated by measuring the Pearson’s correlation coefficient between the SNAQ and Mini-Nutritional Assessment (MNA) and Patient-Generated Subjective Global Assessment (PG-SGA).
Results
In the 194 patients included in full analysis set, cancer stage was predominantly metastatic (98.5%), the mean age was 60 years (range, 23 to 81 years), and the mean body mass index was 24 kg/m2 (range, 15.6 to 39.6 kg/m2). According to MNA score ≤ 11, 57 patients (29.4%) were malnourished. The mean score (±standard deviation) of the Korean version of the SNAQ was 13.8±2.5 with a range of 6-19. Cronbach’s alpha coefficient was 0.737, and intraclass correlation coefficient was 0.869. The SNAQ was moderately correlated with MNA (r=0.404, p < 0.001) and PG-SGA (r=–0.530, p < 0.001). A significant weight loss of > 5% of the original bodyweightwithin 6 months occurred in 46 of the 186 patients (24.7%). SNAQ score ≤ 14 predicted > 5% weight loss with a sensitivity of 56.5% and a specificity of 44.3%.
Conclusion
The Korean version of the SNAQ had high validity and reliability. SNAQ is useful for the screening tool for advanced cancer patients. The SNAQ had a limitation to predict impending weight loss in advanced cancer patients.

Citations

Citations to this article as recorded by  
  • Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ
    Naoki Hiki, Tadashi Higuchi, Koshi Kumagai, Kota Okuno, Hiroyuki Minoura, Yumi Sato, Shohei Fujita, Hiroki Harada, Motohiro Chuman, Marie Washio, Mikiko Sakuraya, Masahiro Niihara, Yusuke Kumamoto, Takeshi Naitoh, Keishi Yamashita
    Gastric Cancer.2025;[Epub]     CrossRef
  • Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
    Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
    European Journal of Oncology Nursing.2024; 68: 102497.     CrossRef
  • Therapeutic Potential of Combined Herbal Medicine and Electroacupuncture in Mild Cognitive Impairment Through Cytokine Modulation: An Observational Study
    Jung-Hee Jang, Hyeong Joon Jun, ChaYoung Lee, Eunjin Sohn, Ojin Kwon, Dong-Hoon Kang, Muhammad Umar, In Chul Jung, Soo-Jin Jeong
    Neuropsychiatric Disease and Treatment.2024; Volume 20: 1331.     CrossRef
  • Reliability and validity of Chinese version of the Simplified Nutritional Appetite Questionnaire (SNAQ) in community-dwelling old people
    Gaojie Feng, Xiaohong Sun, Qiumei Wang, Fei Lu, Yuanyuan Li, Yaru Zhou, Xiaohong Liu
    Geriatric Nursing.2024; 59: 351.     CrossRef
  • Malnutrition risk screening in adult oncology outpatients: An ASPEN systematic review and clinical recommendations
    Elaine B. Trujillo, Kunal C. Kadakia, Cynthia Thomson, Fang Fang Zhang, Alicia Livinski, Kim Pollard, Todd Mattox, Anne Tucker, Valaree Williams, Declan Walsh, Steven Clinton, Aaron Grossberg, Gordon Jensen, Rhone Levin, Jeannine Mills, Anurag Singh, Mere
    Journal of Parenteral and Enteral Nutrition.2024; 48(8): 874.     CrossRef
  • Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
    Konstantina Vamvakari, Iliana Evangelou, Ioanna Panagiota Kalafati, Michail Kipouros, Rena I. Kosti, Arezina N. Kasti, Odysseas Androutsos
    memo - Magazine of European Medical Oncology.2023; 16(3): 200.     CrossRef
  • AIWW: a new nutrition-screening tool for the oncologic population
    Yi-Zhong Ge, Zhen-Ming Fu, Qi Zhang, Meng-Meng Song, Guo-Tian Ruan, Xi Zhang, Xiao-Wei Zhang, Xiang-Rui Li, Kang-Ping Zhang, Meng Tang, Xiao-Yue Liu, Ming Yang, Tong Liu, Hai-Lun Xie, He-Yang Zhang, Zi-Wen Wang, Chun-Lei Hu, Shi-Qi Lin, Rui Zhang, Hong-Xi
    Science China Life Sciences.2023; 66(8): 1831.     CrossRef
  • Validation of a telephone‐based administration of the simplified nutritional appetite questionnaire
    Binh Duong Thai, Jürgen M. Bauer, Annette Eidam, Jane Durga, Stefan Grund, Thomas Mross, Petra Benzinger
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1848.     CrossRef
  • Faeces from malnourished colorectal cancer patients accelerate cancer progression
    Xu Chao, Zhang Lei, Liu Hongqin, Wang Ziwei, Li Dechuan, Du Weidong, Xu Lu, Chen Haitao, Zhang Bo, Ju Haixing, Yao Qinghua
    Clinical Nutrition.2022; 41(3): 632.     CrossRef
  • Influence of cognitive function and nurse support on malnutrition risk in nursing home residents
    Annamária Pakai, Emese Havasi‐Sántha, Erzsébet Mák, Orsolya Máté, Dorina Pusztai, Noémi Fullér, Miklós Zrínyi, András Oláh
    Nursing Open.2021; 8(4): 1805.     CrossRef
  • Effectiveness of Oral Nutritional Supplements on Older People with Anorexia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Mengqi Li, Si Zhao, Shuang Wu, Xiufen Yang, Hui Feng
    Nutrients.2021; 13(3): 835.     CrossRef
  • Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression
    Yajun Wang, Shan Ye, Lu Chen, Lu Tang, Dongsheng Fan
    Scientific Reports.2021;[Epub]     CrossRef
  • Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
    Sue Youn Kim, Jae Moon Yun, Ji-Won Lee, Young Gyu Cho, Kyung-Hwan Cho, Yong Gyu Park, Belong Cho
    Clinical Therapeutics.2021; 43(10): 1757.     CrossRef
  • Development of Korean Frailty Index for Primary Care (KFI-PC) and Its Criterion Validity
    Chang Won Won, Yunhwan Lee, Seoyoon Lee, Miji Kim
    Annals of Geriatric Medicine and Research.2020; 24(2): 125.     CrossRef
  • The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults
    Sabrina Lau, Kalene Pek, Justin Chew, Jun Pei Lim, Noor Hafizah Ismail, Yew Yoong Ding, Matteo Cesari, Wee Shiong Lim
    Nutrients.2020; 12(9): 2885.     CrossRef
  • 8,417 View
  • 208 Download
  • 17 Web of Science
  • 15 Crossref
Close layer
Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy
Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Soojung Hong, Tae-Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun-Mo Ryoo, Kyung Hee Lee, Jee Hyun Kim
Cancer Res Treat. 2019;51(3):1249-1256.   Published online January 2, 2019
DOI: https://doi.org/10.4143/crt.2018.451
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to prospectively validate the Korean Cancer Study Group Geriatric Score (KG)-7, a novel geriatric screening tool, in older patients with advanced cancer planned to undergo first-line palliative chemotherapy.
Materials and Methods
Participants answered the KG-7 questionnaire before undergoing geriatric assessment (GA) and first-line palliative chemotherapy. The performance of KG-7 was evaluated by calculating the sensitivity (SE), specificity (SP), positive and negative predictive value (PPV and NPV), balanced accuracy (BA), and area under the curve (AUC).
Results
The baseline GA and KG-7 results were collected from 301 patients. The median age was 75 years (range, 70 to 93 years). Abnormal GA was documented in 222 patients (73.8%). Based on the ≤ 5 cut-off value of KG-7 for abnormal GA, abnormal KG-7 score was shown in 200 patients (66.4%). KG-7 showed SE, SP, PPV, NPV, and BA of 75.7%, 59.7%, 84.4%, 46.0%, and 67.7%, respectively; AUC was 0.745 (95% confidence interval, 0.687 to 0.803). Furthermore, patients with higher KG-7 scores showed significantly longer survival (p=0.006).
Conclusion
KG-7 appears to be adequate in identifying patients with abnormal GA prospectively. Hence, KG-7 can be a useful screening tool for Asian countries with limited resources and high patient volume.

Citations

Citations to this article as recorded by  
  • Comparison of two frailty screening tools in older patients with colorectal cancer
    Han Zhao, Xinlin Lu, Senshuang Zheng, Danmei Wei, Lizhong Zhao, Yuan Wang, Geertruida H. de Bock, Wenli Lu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
    In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee,
    Cancers.2021; 13(2): 331.     CrossRef
  • A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
    Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
    Journal of Geriatric Oncology.2021; 12(6): 922.     CrossRef
  • Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)
    Helena Møgelbjerg Ditzel, Ann-Kristine Weber Giger, Cecilia Margareta Lund, Henrik Jørn Ditzel, Afsaneh Mohammadnejad, Per Pfeiffer, Jesper Ryg, Trine Lembrecht Jørgensen, Marianne Ewertz
    Journal of Geriatric Oncology.2021; 12(8): 1270.     CrossRef
  • The Globalization of Geriatric Oncology: From Data to Practice
    Ravindran Kanesvaran, Supriya Mohile, Enrique Soto-Perez-de-Celis, Harpreet Singh
    American Society of Clinical Oncology Educational Book.2020; (40): e107.     CrossRef
  • 9,723 View
  • 180 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives
Su-Jin Koh, Shinmi Kim, JinShil Kim, Bhumsuk Keam, Dae Seog Heo, Kyung Hee Lee, Bong-Seog Kim, Jee Hyun Kim, Hye Jung Chang, Sun Kyung Baek
Cancer Res Treat. 2018;50(2):614-623.   Published online July 3, 2017
DOI: https://doi.org/10.4143/crt.2016.446
AbstractAbstract PDFPubReaderePub
Purpose
The aims of this study were to explore how oncologists and resident physicians practice end-of-life (EOL) discussions and to solicit their opinions on EOL discussions as a means to improve the quality of EOL care.
Materials and Methods
A survey questionnaire was developed to explore the experiences and opinions about EOL discussions among oncologists and residents. Descriptive statistics, the t test, and the chisquare test were performed for the analyses.
Results
A total of 147 oncologists and 229 residents participated in this study. The study respondents reported diverse definitions of “terminal state,” and mostrespondents tried to disclose the patient’s condition to the patient and/or family members. Both groups were involved in EOL care discussions, with a rather low satisfaction level (57.82/100). The best timing to initiate discussionwas consideredwhen metastasis or disease recurrence occurred orwhen withdrawal of chemotherapy was anticipated. Furthermore, the study respondents suggested that patients and their family members should be included in the EOL discussion. Medical, legal, and ethical knowledge and communication difficulties along with practical issues were revealed as barriers and facilitators for EOL discussion.
Conclusion
This study explored various perspectives of oncologists and resident physicians for EOL discussion. Since the Life-Sustaining-Treatment Decision-Making Act will be implemented shortly in Korea, now is the time for oncologists and residents to prepare themselves by acquiring legal knowledge and communication skills. To achieve this, education, training, and clinical tools for healthcare professionals are required.

Citations

Citations to this article as recorded by  
  • Physicians are over optimistic in recognizing inpatients’ survival and palliative care needs: a large-scale multi-center study in Taiwan
    C -M Huang, S -J Huang, T -Y Wu, Y -C Chen, S -H Hsiao, D Chu
    QJM: An International Journal of Medicine.2024; 117(3): 195.     CrossRef
  • The quality of dying and death of patients with cancer from Shanghai in China from the perspective of healthcare providers: A cross-sectional study
    Jiawei Min, Peihao Liu, Kaifeng Xiao, Zhe Huang, Xiaobin Lai
    International Journal of Nursing Sciences.2024; 11(2): 179.     CrossRef
  • Issues and implications of the life-sustaining treatment decision act: comparing the data from the survey and clinical data of inpatients at the end-of-life process
    Eunjeong Song, Dongsoon Shin, Jooseon Lee, Seonyoung Yun, Minjeong Eom, Suhee Oh, Heejung Lee, Jiwan Lee, Rhayun Song
    BMC Medical Ethics.2024;[Epub]     CrossRef
  • Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study
    Hyeon-Su Im, Insook Lee, Shinmi Kim, Jong Soo Lee, Ju-Hee Kim, Jae Young Moon, Byung Kyu Park, Kyung Hee Lee, Myung Ah Lee, Sanghoon Han, Yoonki Hong, Hyeyeoung Kim, Jaekyung Cheon, Su-Jin Koh
    BMC Medical Ethics.2023;[Epub]     CrossRef
  • Barriers and facilitators that hospital clinicians perceive to discuss the personal values, wishes, and needs of patients in palliative care: a mixed-methods systematic review
    Sita de Vries, Mary-Joanne Verhoef, Sigrid Cornelia Johanna Maria Vervoort, Yvette Milene van der Linden, Saskia Cornelia Constantia Maria Teunissen, Everlien de Graaf
    Palliative Care and Social Practice.2023;[Epub]     CrossRef
  • Association Among End-Of-Life Discussions, Cancer Patients’ Quality of Life at End of Life, and Bereaved Families’ Mental Health
    Yoko Hayashi, Kazuki Sato, Masahiro Ogawa, Yoshiro Taguchi, Hisashi Wakayama, Aya Nishioka, Chikako Nakamura, Kaoru Murota, Ayumi Sugimura, Shoko Ando
    American Journal of Hospice and Palliative Medicine®.2022; 39(9): 1071.     CrossRef
  • Difficulties Facing Junior Physicians and Solutions Toward Delivering End-of-Life Care for Patients with Cancer: A Nationwide Survey in Japan
    Soichiro Okamoto, Yu Uneno, Natsuki Kawashima, Shunsuke Oyamada, Yusuke Hiratsuka, Keita Tagami, Manabu Muto, Tatsuya Morita
    Palliative Medicine Reports.2022; 3(1): 255.     CrossRef
  • The silent transition from curative to palliative treatment: a qualitative study about cancer patients’ perceptions of end-of-life discussions with oncologists
    A. Kitta, A. Hagin, M. Unseld, F. Adamidis, T. Diendorfer, E. K. Masel, K. Kirchheiner
    Supportive Care in Cancer.2021; 29(5): 2405.     CrossRef
  • Advance Care Planning in Asia: A Systematic Narrative Review of Healthcare Professionals’ Knowledge, Attitude, and Experience
    Diah Martina, Cheng-Pei Lin, Martina S. Kristanti, Wichor M. Bramer, Masanori Mori, Ida J. Korfage, Agnes van der Heide, Carin C.D. van der Rijt, Judith A.C. Rietjens
    Journal of the American Medical Directors Association.2021; 22(2): 349.e1.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
    Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
    BMC Palliative Care.2021;[Epub]     CrossRef
  • Act on Decisions on Life-Sustaining Treatment and Timing of Referral to Hospice
    Han-na Ju, Seung Hun Lee, Yun-Jin Kim, Sang-Yeoup Lee, Jeong-Gyu Lee, Yu-Hyeon Yi, Young-Hye Cho, Young-Jin Tak, Hye-Rim Hwang, Eun-Ju Park, Young-In Lee
    Korean Journal of Family Practice.2021; 11(5): 331.     CrossRef
  • Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study
    Lara Traeger, Chelsea Rapoport, Emily Wright, Areej El-Jawahri, Joseph A. Greer, Elyse R. Park, Vicki A. Jackson, Jennifer S. Temel
    Journal of Palliative Medicine.2020; 23(4): 542.     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Differences in perspectives of pediatricians on advance care planning: a cross-sectional survey
    In Gyu Song, Sung Han Kang, Min Sun Kim, Cho Hee Kim, Yi Ji Moon, Jung Lee
    BMC Palliative Care.2020;[Epub]     CrossRef
  • Feasibility of a team based prognosis and treatment goal discussion (T-PAT) with women diagnosed with advanced breast cancer
    Mary M. Step, Gretchen A. Ferber, Catherine Downs-Holmes, Paula Silverman
    Patient Education and Counseling.2019; 102(1): 77.     CrossRef
  • Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act
    Hye Yoon Park, Young Ae Kim, Jin-Ah Sim, Jihye Lee, Hyewon Ryu, Jung Lim Lee, Chi Hoon Maeng, Jung Hye Kwon, Yu Jung Kim, Eun Mi Nam, Hyun-Jeong Shim, Eun-Kee Song, Kyung Hae Jung, Eun Joo Kang, Jung Hun Kang, Young Ho Yun
    Journal of Pain and Symptom Management.2019; 57(4): 774.     CrossRef
  • Family-clinician communication in the ICU and its relationship to psychological distress of family members: A cross-sectional study
    Minjeong Jo, Mi-Kyung Song, George J. Knafl, Linda Beeber, Yang-Sook Yoo, Marcia Van Riper
    International Journal of Nursing Studies.2019; 95: 34.     CrossRef
  • Implementation of Antimicrobial Stewardship Programs in End-of-Life Care
    Ki Tae Kwon
    Infection & Chemotherapy.2019; 51(2): 89.     CrossRef
  • Facilitators and Barriers to Oncologists’ Conduct of Goals of Care Conversations
    Dena Schulman-Green, Jenny J. Lin, Cardinale B. Smith, Shelli Feder, Nina A. Bickell
    Journal of Palliative Care.2018; 33(3): 143.     CrossRef
  • Clinical characteristics and survival outcomes of terminally ill patients undergoing withdrawal of mechanical ventilation
    Yu-Shin Hung, Shu-Hui Lee, Chia-Yen Hung, Chao-Hui Wang, Chen-Yi Kao, Hung-Ming Wang, Wen-Chi Chou
    Journal of the Formosan Medical Association.2017;[Epub]     CrossRef
  • 10,116 View
  • 268 Download
  • 22 Web of Science
  • 22 Crossref
Close layer
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung
Cancer Res Treat. 2017;49(2):423-429.   Published online August 3, 2016
DOI: https://doi.org/10.4143/crt.2016.191
AbstractAbstract PDFPubReaderePub
Purpose
Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC),who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials.
Materials and Methods
In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease.
Results
A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively.
Conclusion
This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.

Citations

Citations to this article as recorded by  
  • Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
    Yu-Ju Lin, Chun-Nan Kuo, Yu Ko
    The Breast.2021; 57: 18.     CrossRef
  • Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
    Pei-Hsin Chen, Dah-Cherng Yeh, Heng-Hsin Tung, Chin-Yao Lin
    Medicine.2021; 100(47): e27859.     CrossRef
  • Multifarious targets beyond microtubules—role of eribulin in cancer therapy
    Priya Seshadri, Barnali Deb, Prashant Kumar
    Frontiers in Bioscience-Scholar.2021;[Epub]     CrossRef
  • A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
    Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh, Geumhee Gwak, Tae Hyun Kim, Young Bum Yoo, Hyun-Ah Kim, Min Young Kim, Ju Yeon Kim, Joon Jeong
    The Breast.2020; 54: 121.     CrossRef
  • Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
    Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu, Ming-Hung Hu, Yin-Che Lu, Wei-Jen Ou, Chin-Ho Kuo, Chieh-Han Chuang, Jung-Yu Kan, Fang-Ming Chen, Ming-Feng Hou
    Breast Cancer Research and Treatment.2018; 170(3): 583.     CrossRef
  • Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
    Bin Zhao, Hong Zhao, Jiaxin Zhao
    Critical Reviews in Oncology/Hematology.2018; 128: 110.     CrossRef
  • Angiomodulators in cancer therapy: New perspectives
    Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Büsselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak
    Biomedicine & Pharmacotherapy.2017; 89: 578.     CrossRef
  • Eribulin in Advanced Breast Cancer: Safety, Efficacy and New Perspectives
    Ornella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua, Marco C Merlano
    Future Oncology.2017; 13(30): 2759.     CrossRef
  • Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
    Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang, Qiong Zhao
    Oncotarget.2017; 8(67): 112076.     CrossRef
  • 12,007 View
  • 333 Download
  • 6 Web of Science
  • 9 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP